Ryman unaudited first half underlying profit of $138.8m

Ryman Healthcare has reported an unaudited first half underlying profit of $138.8 million, up 44.8% on the same period last year.

This was driven by strong resales margins as well as continued strong growth in its Australian business.

Shareholders will receive an interim dividend of 8.8 cents per share, unchanged from last year, and a dividend reinvestment plan has been established.

The Group CEO Richard Umbers noted Ryman was now an established trans-Tasman business, with booked sales of occupation rights up 9.8% driven by strong growth in Australia.

The Chairman Greg Campbell commented that it was a pleasing result in a year characterised by increasing uncertainty.

George Savvides will retire from the Board of Directors after 10 years in July 2023.